$JNJ insider trading
Over the last 12 months, Johnson & Johnson insiders reported 1 buy totaling $258K and 16 sales totaling $154.9M across SEC Form 4 filings.
- Bought · 12m
- $258K 1 event
- Sold · 12m
- $154.9M 16 events
- Events · 12m
- 17 Form 4 filings, grouped
- Insiders · 12m
- 11 distinct reporters
- 10b5-1 share
- 0% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Schmid TimothyEVP, WW Chair, MedTech · O | ▼ Sale | 33,597 | $274.74 | $9.2M | -56.9% | 2 tranches |
| Aug 17, 2026 | Taubert Jennifer LEVP, WWC. Innovative Medicine · O | ▼ Sale | 15,000 | $263.36 | $4.0M | -7.2% | — |
| Aug 13, 2026 | Duato JoaquinCEO and Chairman of the Board · O·D | ▼ Sale | 123,291 | $261.17 | $32.2M | -30.9% | 2 tranches |
| Aug 6, 2026 | Forminard ElizabethEVP, Chief Legal Officer · O | ▼ Sale | 15,918 | $257 | $4.1M | -48.4% | 2 tranches |
| Aug 5, 2026 | Duato JoaquinCEO and Chairman of the Board · O·D | ▼ Sale | 48,480 | $258.15 | $12.5M | -14.9% | 2 tranches |
| Jul 20, 2026 | Broadhurst VanessaEVP, Global Corp Affairs · O | ▼ Sale | 23,054 | $251.27 | $5.8M | -50.1% | — |
| Jun 11, 2026 | Wengel Kathryn EEVP, Chief TO and Risk Officer · O | ▼ Sale | 10,000 | $241.15 | $2.4M | -8% | — |
| Feb 27, 2026 | Decker Robert JVP Corporate Controller · O | ▼ Sale | 4,075 | $247.87 | $1.0M | -14.7% | — |
| Feb 20, 2026 | Schmid TimothyEVP, WW Chair, MedTech · O | ▼ Sale | 1,322 | $245.66 | $325K | -4.9% | — |
| Feb 18, 2026 | Schmid TimothyEVP, WW Chair, MedTech · O | ▼ Sale | 22,623 | $244.33 | $5.5M | -45.8% | 2 tranches |
| Feb 17, 2026 | Swanson James D.EVP, CIO · O | ▼ Sale | 62,080 | $243.39 | $15.1M | -70.7% | 3 tranches |
| Feb 17, 2026 | Wolk Joseph JExec VP, CFO · O | ▼ Sale | 89,654 | $242.8 | $21.8M | -86.5% | 4 tranches |
| Feb 17, 2026 | REED JOHN CEVP, Innovative Medicine, R&D · O | ▼ Sale | 53,931 | $243 | $13.1M | -83.5% | 3 tranches |
| Feb 17, 2026 | Broadhurst VanessaEVP, Global Corp Affairs · O | ▼ Sale | 6,197 | $243.39 | $1.5M | -21.2% | — |
| Jan 26, 2026 | Duato JoaquinCEO and Chairman of the Board · O·D | ▼ Sale | 100,000 | $221.23 | $22.1M | -76.4% | 2 tranches · indirect |
| Nov 26, 2025 | MORIKIS JOHN GD | ▲ Buy | 1,250 | $206.15 | $258K | +208.9% | — |
| Oct 17, 2025 | REED JOHN CEVP, Innovative Medicine, R&D · O | ▼ Sale | 21,721 | $192.71 | $4.2M | -67.1% | — |
| Sep 4, 2025 | Taubert Jennifer LEVP, WWC. Innovative Medicine · O | ▼ Sale | 56,471 | $177.81 | $10.0M | -24.1% | — |
| Aug 22, 2025 | Duato JoaquinCEO and Chairman of the Board · O·D | ▼ Sale | 125,824 | $179.21 | $22.5M | -31.3% | — |
| Aug 15, 2025 | Wolk Joseph JExec VP, CFO · O | ▼ Sale | 16,820 | $176.91 | $3.0M | -54.6% | — |
Every $JNJ filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Johnson & Johnson filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $JNJ feed.